Principia Biopharma Inc. (PRNB): Price and Financial Metrics
PRNB Price/Volume Stats
| Current price | $100.05 | 52-week high | $101.89 |
| Prev. close | $99.95 | 52-week low | $25.35 |
| Day low | $99.95 | Volume | 1,792,700 |
| Day high | $100.37 | Avg. volume | 729,676 |
| 50-day MA | $94.52 | Dividend yield | N/A |
| 200-day MA | $68.53 | Market Cap | 3.32B |
PRNB Stock Price Chart Interactive Chart >
Principia Biopharma Inc. (PRNB) Company Bio
Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was founded in 2008 and is based in South San Francisco, California.
Latest PRNB News From Around the Web
Below are the latest news stories about Principia Biopharma Inc that investors may wish to consider to help them evaluate PRNB as an investment opportunity.
dosing underway for Principia's rilzabrutinib mid-stage study in IgG4-related diseasePrincipia Biopharma (PRNB) has dosed the first patient in an open label two-arm Phase 2A trial, evaluating rilzabrutinib in IgG4-related disease ((RD)), an immune-mediated fibroinflammatory condition that is capable of affecting multiple organs.The 25-subject trial has a primary endpoint of the proportion of patients who achieve complete remission at week 12 with... |
A biopharma with 54% upside, with or without M&A - EvercoreChatter about a potential buyout has lifted the stock of immune-disorder therapy developer Principia Biopharma (PRNB) - shares are up 13.6% since Sanofi (SNY) was linked to interest, and they're up 49% over the past three weeks - but a takeover isn't even part of the thesis in a bullish... |
Why Principia Could Be the Next Target of Sanofi's MakeoverBuyout rumors have spurred a sharp increase in the small biotech’s shares Continue reading... |
Principia Biopharma Soars as Sanofi Is Said to Seek DealsSanofi is reportedly looking at potential acquisitions of U.S. biotechs. Principia Biopharma shares jumped on the report. |
Principia Biopharma (PRNB) Jumps: Stock Rises 6.8%Principia Biopharma (PRNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. |
PRNB Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 60.08% |
| 5-year | N/A |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | 100.00% |
| 2018 | N/A |
Continue Researching PRNB
Here are a few links from around the web to help you further your research on Principia Biopharma Inc's stock as an investment opportunity:Principia Biopharma Inc (PRNB) Stock Price | Nasdaq
Principia Biopharma Inc (PRNB) Stock Quote, History and News - Yahoo Finance
Principia Biopharma Inc (PRNB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...